Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill VX-993 tested for Post-Surgery pain relief

NCT ID NCT06619847

Symptom relief Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested the drug VX-993 in 367 people who had bunion surgery. The goal was to see if it safely reduces acute pain compared to a placebo. Participants took VX-993 tablets or a placebo, and researchers measured pain intensity over 48 hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VX-993 (oral tablet)
What this could lead to
If successful, this could provide a new option for managing short-term pain after surgery.
What could go wrong
This is an early-phase trial (Phase 2) with a small sample focused on one surgery type. Results may not apply to other pain types, and the drug may not prove effective or safe enough for approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

367 people

The number who actually took part.

Started

Oct 2024

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: Before Surgery: * Participant scheduled to undergo a primary unilateral bunionectomy with distal first metatarsal osteotomy (i.e., Austin procedure) and internal fixation under regional anesthesia (Mayo block) After Surgery: * Participant is lucid and able to follow commands * All analgesic guidelines were followed during and after the bunionectomy Key Exclusion Criteria: Before Surgery: * Prior history of bunionectomy or other foot surgery on the index foot * History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) within the last 2 years * A known or clinically suspected active infection with human immunodeficiency virus or hepatitis B or C viruses After Surgery: * Participant had a Type 3 deformity requiring a base wedge osteotomy or concomitant surgery such as hammertoe repair, or had medical complications during the bunionectomy Other protocol defined inclusion/exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain

Contacts and locations

Locations

  • Arizona Research Center

    Phoenix, Arizona, 85053, United States

  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30331, United States

  • BioBehavioral Research of Austin

    Austin, Texas, 78759, United States

  • Clinical Pharmacology of Miami

    Miami, Florida, 33172, United States

  • Endeavor Clinical Trials

    San Antonio, Texas, 78240, United States

  • ForCare Clinical Research

    Tampa, Florida, 33613, United States

  • HD Research LLC | First Surgical Hospital

    Bellaire, Texas, 77401, United States

  • HD Research LLC | Legent Orthopedic Hospital

    Carrollton, Texas, 75006, United States

  • JBR Clinical Research

    Salt Lake City, Utah, 84107, United States

  • Memorial Hermann Village

    Houston, Texas, 77043, United States

  • New Hope Research Development | Tarzana, CA

    Tarzana, California, 91356, United States

  • Shoals Medical Trials Inc.

    Sheffield, Alabama, 35660, United States

  • Trovare Clinical Research

    Bakersfield, California, 93301, United States

  • Woodland International Research Group

    Little Rock, Arkansas, 72211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.